SAN DIEGO–Illumina, Inc., (NASDAQ:ILMN – News) today announced that Mitsubishi Chemical Safety Institute, a provider of various analyses, examinations, and services for pharmaceutical companies, public institutions, and chemical companies, is the first organization in Japan to become an Illumina CSPro® (certified service provider). Illumina CSPro is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Mitsubishi Chemical Safety Institute offers its customers whole-genome and targeted-genotyping services using Illumina’s Infinium® and GoldenGate® Assays. Both assays leverage Illumina’s proprietary BeadArray® technology to provide customers the ability to perform large-scale interrogation of the human genome, which enables them to cost-effectively fast forward their research and identify genetic variants linked to disease. “For the last seven years, we have concentrated on the investigation of toxicogenomics and pharmacogenomics, and have consequently acquired an abundance of experience in the development of genomic analysis technologies,” said Masaru Sekijima, Ph.D., General Manager of Advanced Medical Science Research Center, Mitsubishi Chemical Safety Institute. “As a result of this hard work, we are excited to become the first Illumina CSPro in Japan, making it possible to provide researchers with the level of high-quality genomic data customers have come to expect from Illumina.” Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes. To find out more about Illumina’s CSPro program, please visit www.illumina.com/cspro. “Interest in the Illumina CSPro program continues to grow with more than 20 academic and commercial technology providers already certified or in the process of certification. Now that Mitsubishi Chemical Safety Institute is a partner, we are excited to work with them to make it easier for researchers in Japan to access the power of Illumina’s genetic analysis technologies,” said Karen Possemato, Director of Corporate Marketing at Illumina. About Mitsubishi Chemical Safety Institute Mitsubishi Chemical Safety Institute (www.anaken.co.jp) provides various analyses, examinations, and services for pharmaceutical companies, public institutions, and chemical companies. Since the establishment of Mitsubishi Chemical Medience group in April 2007, Mitsubishi Chemical Safety Institute has supported drug development businesses seamlessly from pre-clinical trials to clinical trials in cooperation with Mitsubishi Chemical Medience Corporation. Since establishing the Advanced Medical Science Research Center in April 2008, Mitsubishi Chemical Safety Institute has taken a progressive approach for development of pharmacodynamics and safety evaluation technologies for drugs based on genomics, cellomics, and phenomics by introducing genome-wide analysis technology, as well as conventional gene analysis. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (iii) to manufacture robust microarrays and Oligator® oligonucleotides, (iv) to integrate and scale our VeraCode technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.